Tweet
<img alt="" height="1" width="1" />
Vivus obesity drug may get broader label
Reuters
(Reuters) - Vivus Inc said US health regulators asked the company to remove a contraindication in the proposed label of its obesity drug Qnexa, a move that could help it reach a broader patient population. Shares of the company rose as much as 17 ...
Vivus To Cut Child-Bearing Line From Diet Drug LabelWall Street Journal
Vivus Rises on FDA-Ordered Change to Weight-Loss Pill LabelBusinessWeek
Vivus: FDA drops restriction on diet-drug QnexaMarketWatch
FierceBiotech -Bloomberg -Pharmaceutical Processing
all 24 news articles »
More...